- Home
- FEMY vs CLDI Comparison
FEMY vs CLDI Comparison
Compare FEMY & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- CLDI
- Stock Information
- Founded
- FEMY 2004
- CLDI 2014
- Country
- FEMY United States
- CLDI United States
- Employees
- FEMY 71
- CLDI N/A
- Industry
- FEMY Medical/Dental Instruments
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FEMY Health Care
- CLDI Health Care
- Exchange
- FEMY Nasdaq
- CLDI Nasdaq
- Market Cap
- FEMY 23.1M
- CLDI 20.2M
- IPO Year
- FEMY 2021
- CLDI N/A
- Fundamental
- Price
- FEMY $0.71
- CLDI $5.30
- Analyst Decision
- FEMY Strong Buy
- CLDI
- Analyst Count
- FEMY 3
- CLDI 0
- Target Price
- FEMY $7.33
- CLDI N/A
- AVG Volume (30 Days)
- FEMY 238.0K
- CLDI 961.3K
- Earning Date
- FEMY 08-08-2025
- CLDI 08-08-2025
- Dividend Yield
- FEMY N/A
- CLDI N/A
- EPS Growth
- FEMY N/A
- CLDI N/A
- EPS
- FEMY N/A
- CLDI N/A
- Revenue
- FEMY $1,887,016.00
- CLDI N/A
- Revenue This Year
- FEMY $283.83
- CLDI N/A
- Revenue Next Year
- FEMY $161.03
- CLDI N/A
- P/E Ratio
- FEMY N/A
- CLDI N/A
- Revenue Growth
- FEMY 98.61
- CLDI N/A
- 52 Week Low
- FEMY $0.69
- CLDI $2.43
- 52 Week High
- FEMY $1.80
- CLDI $46.68
- Technical
- Relative Strength Index (RSI)
- FEMY 34.99
- CLDI 44.17
- Support Level
- FEMY $0.72
- CLDI $4.85
- Resistance Level
- FEMY $1.00
- CLDI $6.06
- Average True Range (ATR)
- FEMY 0.06
- CLDI 1.03
- MACD
- FEMY -0.01
- CLDI -0.31
- Stochastic Oscillator
- FEMY 0.89
- CLDI 8.91
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.